Breast cancer
PRINCIPAL INVESTIGATORS
- Amparo García Tejedor
CLINICAL RESEARCHERS
- Catalina Falo Zamora
- Adela Fernández Ortega
- Bartomeu Fullana Grimalt
- Juan Miguel Gil Gil
- Veronica Luisa Obadia Gil
- Anna Petit Montserrat
- Maria Jesus Pla Farnos
- Sabela Recalde Penabad
- Agostina Stradella Trucco
- Silvia Vázquez Fernández
- Rafael Villanueva Vázquez
POSTDOCTORAL RESEARCHERS
- Ricard Bonilla Amadeo
PREDOCTORAL RESEARCHERS
- Julia Migo Aran
- Aintzane Rodriguez Barrante
- Sen Zhao
MANAGEMENT SUPPORT
- Ivan Domenech Mercade
SCIENTIFIC SUPPORT
- Marc Alegre Herranz
- Oscar Padilla Martinez
- Mario Rodriguez Perez
- Carlos Yeste Vergara
Cancer
Oncobell
Scientific production
28
PAPERS
Average IF: 13,46
5
LED PAPERS
Average IF: 3,52
8 PUBLICATIONS IN FIRST DECILE
21 PUBLICATIONS IN FIRST QUARTILE
25 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Vethencourt,A;Trinidad,EM;Dorca,E;Petit,A;Soler Monso,MT;Ciscar,M;Barranco,A et al, Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial, Breast Cancer Res, 2025;27(1):68-68, doi:10.1186/s13058-025-01996-w
- Pla,H;Fullana,B;Esteve,A;Fort Culillas,R;Ferrando Diez,A;Fernandez Ortega,A;Pous,A et al, Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Catala d’Oncologia Breast Cancer Observational Cohort Study, Cancers, 2025;17(8); doi:10.3390/cancers17081366
- Bidard,FC;Mayer,EL;Park,YH;Janni,W;Ma,C;Cristofanilli,M;Bianchini,G et al, First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer., N Engl J Med, 2025;393(6):569-580, doi:10.1056/NEJMoa2502929,
- Gion,M;Blancas,I;Cortez Castedo,P;Cortes Salgado,A;Marme,F;Blanch,S;Morales,S et al, Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial, Nat. Med., 2025;31(8):2746-2754; doi:10.1038/s41591-025-03734-3
- Bardia,A;Jhaveri,K;Im,SA;Pernas,S;De Laurentiis,M;Wang,S;Martínez Jañez,N et al, Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01., J. Clin. Oncol., 2025;43(3):285-296, doi:10.1200/JCO.24.00920
Research highlights
PROJECTS
3 Granted competitive projects
7 Ongoing competitive projects
14 Started clinical trials
50 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical Guideline
1 Thesis
NETWORKS
CIMBA
ENBDC
AGAUR SGR 2017-449
LOBSTERPOT
Immuno-Model COST Action
Selected projects
- PI24/01014. Impacto sobre el dolor pélvico y la Calidad de Vida de la Punción-Esclerosis con Alcohol vs. Manejo expectante en Pacientes con Endometriomas (Estudio ESCOMA). Instituto de Salud Carlos III (ISCIII). Budget: 152.500€. 2025-2027. PI: AMPARO GARCÍA TEJEDOR.
- SLT042/25/000047. Concessió de subvencions PERIS 2025 . Generalitat de Catalunya. Budget: 149.760€. 2025-2028. PI: SONIA PERNAS SIMÓN.
- PMP22/00032. Integración longitudinal de datos generados por paciente y determinaciones multi-omicas para una oncología de precisión integral en cáncer de la mujer. Instituto de Salud Carlos III (ISCIII). Budget: 87.745,09€. 2023-2026. PI: SONIA PERNAS SIMÓN.
- CompreHensIve study of MEtaplastic bReast cArcinomas (CHIMERA study): A heterogeneous disease with poor prognosis. ASOCIACIÓN DE CÁNCER DE MAMA METASTÁSICO CMM. Budget: 80.000€. 2025-2027. PI: SONIA PERNAS SIMÓN.
- PI20/00544. Perfil transcriptómico precoz durante el tratamiento como marcador predictivo de respuesta en Cáncer de Mama HER2-positivo. Instituto de Salud Carlos III (ISCIII). Budget: 75.020€. 2021-2025. PI: Pernas Simón, Sonia.